Published in Cancer on June 01, 2000
ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med (2010) 13.07
Ovarian cancer. Annu Rev Pathol (2009) 4.92
Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma. Am J Pathol (2009) 3.90
Expression profiling in ovarian clear cell carcinoma: identification of hepatocyte nuclear factor-1 beta as a molecular marker and a possible molecular target for therapy of ovarian clear cell carcinoma. Am J Pathol (2003) 1.94
Therapeutic strategies in epithelial ovarian cancer. J Exp Clin Cancer Res (2012) 1.85
Ovarian carcinomas: five distinct diseases with different origins, genetic alterations, and clinicopathological features. Virchows Arch (2012) 1.80
Ovarian cancer pathogenesis: a model in evolution. J Oncol (2009) 1.77
DNA copy numbers profiles in affinity-purified ovarian clear cell carcinoma. Clin Cancer Res (2010) 1.71
Clear cell carcinoma of the ovary: a retrospective multicentre experience of 254 patients with complete surgical staging. Br J Cancer (2006) 1.67
Salvage chemotherapy for recurrent or persistent clear cell carcinoma of the ovary: a single-institution experience for a series of 20 patients. Int J Clin Oncol (2011) 1.62
Current status of gynecologic cancer in Japan. J Gynecol Oncol (2009) 1.49
Ovarian clear cell adenocarcinoma: a continuing enigma. J Clin Pathol (2006) 1.48
Making the best of PARP inhibitors in ovarian cancer. Nat Rev Clin Oncol (2010) 1.47
Integrated copy number and expression analysis identifies profiles of whole-arm chromosomal alterations and subgroups with favorable outcome in ovarian clear cell carcinomas. PLoS One (2015) 1.44
Molecular abnormalities in ovarian cancer subtypes other than high-grade serous carcinoma. J Oncol (2009) 1.43
mTOR is a promising therapeutic target both in cisplatin-sensitive and cisplatin-resistant clear cell carcinoma of the ovary. Clin Cancer Res (2009) 1.39
Lessons from border cell migration in the Drosophila ovary: A role for myosin VI in dissemination of human ovarian cancer. Proc Natl Acad Sci U S A (2004) 1.34
Cytogenetic alterations in ovarian clear cell carcinoma detected by comparative genomic hybridisation. Br J Cancer (2003) 1.23
WWOX protein expression varies among ovarian carcinoma histotypes and correlates with less favorable outcome. BMC Cancer (2005) 1.22
Identification of novel therapeutic targets in microdissected clear cell ovarian cancers. PLoS One (2011) 1.18
Systematic CpG islands methylation profiling of genes in the wnt pathway in epithelial ovarian cancer identifies biomarkers of progression-free survival. Clin Cancer Res (2011) 1.15
ARID1A mutations and PI3K/AKT pathway alterations in endometriosis and endometriosis-associated ovarian carcinomas. Int J Mol Sci (2013) 1.14
Epigenetic inactivation of TCF2 in ovarian cancer and various cancer cell lines. Br J Cancer (2006) 1.12
New perspectives on molecular targeted therapy in ovarian clear cell carcinoma. Br J Cancer (2013) 1.02
Mucosal carcinoma of the fallopian tube coexists with ovarian cancer of serous subtype only: a study of Japanese cases. Virchows Arch (2010) 0.99
Pathogenesis and the role of ARID1A mutation in endometriosis-related ovarian neoplasms. Adv Anat Pathol (2013) 0.99
Clear cell histology as a poor prognostic factor for advanced epithelial ovarian cancer: a single institutional case series through central pathologic review. J Gynecol Oncol (2013) 0.98
Weekly administration of temsirolimus for heavily pretreated patients with clear cell carcinoma of the ovary: a report of six cases. Int J Clin Oncol (2011) 0.97
Identification of glycoproteins associated with different histological subtypes of ovarian tumors using quantitative glycoproteomics. Proteomics (2011) 0.96
Promoter CpG island methylation of genes in key cancer pathways associates with clinical outcome in high-grade serous ovarian cancer. Clin Cancer Res (2013) 0.93
Fatty acid synthase expression associated with NAC1 is a potential therapeutic target in ovarian clear cell carcinomas. Br J Cancer (2012) 0.92
Expression of membrane type 1 matrix metalloproteinase (MMP-14) in epithelial ovarian cancer: high level expression in clear cell carcinoma. Gynecol Oncol (2008) 0.92
Origin of ovarian cancer: molecular profiling. J Obstet Gynaecol India (2013) 0.91
Clusterin is a potential molecular predictor for ovarian cancer patient's survival: targeting clusterin improves response to paclitaxel. J Exp Clin Cancer Res (2011) 0.91
Potential role of mTORC2 as a therapeutic target in clear cell carcinoma of the ovary. Mol Cancer Ther (2013) 0.91
RECQL1 DNA repair helicase: a potential therapeutic target and a proliferative marker against ovarian cancer. PLoS One (2013) 0.91
Hypomethylation of hepatocyte nuclear factor-1beta (HNF-1beta) CpG island in clear cell carcinoma of the ovary. Virchows Arch (2007) 0.90
Progression-free survival and overall survival of patients with clear cell carcinoma of the ovary treated with paclitaxel-carboplatin or irinotecan-cisplatin: retrospective analysis. Int J Clin Oncol (2007) 0.89
Epigenetic determinants of ovarian clear cell carcinoma biology. Int J Cancer (2014) 0.89
Topotecan as a molecular targeting agent which blocks the Akt and VEGF cascade in platinum-resistant ovarian cancers. Cancer Biol Ther (2010) 0.89
MEK1/2 inhibitor selumetinib (AZD6244) inhibits growth of ovarian clear cell carcinoma in a PEA-15-dependent manner in a mouse xenograft model. Mol Cancer Ther (2011) 0.89
Expression and significance of the TLR4/MyD88 signaling pathway in ovarian epithelial cancers. World J Surg Oncol (2012) 0.88
Human leukocyte antigen class I expression is an independent prognostic factor in advanced ovarian cancer resistant to first-line platinum chemotherapy. Br J Cancer (2009) 0.88
Significant clinical response of progressive recurrent ovarian clear cell carcinoma to glypican-3-derived peptide vaccine therapy: two case reports. Hum Vaccin Immunother (2013) 0.88
p21 Promotes oncolytic adenoviral activity in ovarian cancer and is a potential biomarker. Mol Cancer (2010) 0.87
Agreement for tumor grade of ovarian carcinoma: analysis of archival tissues from the surveillance, epidemiology, and end results residual tissue repository. Cancer Causes Control (2013) 0.87
PEGylated liposome IHL-305 markedly improved the survival of ovarian cancer peritoneal metastasis in mouse. BMC Cancer (2012) 0.86
Promoter methylation status of HIN-1 associated with outcomes of ovarian clear cell adenocarcinoma. Mol Cancer (2012) 0.86
Efficacy of a methyl ester of 5-aminolevulinic acid in photodynamic therapy for ovarian cancers. J Cancer Res Clin Oncol (2010) 0.85
Elevated CDCP1 predicts poor patient outcome and mediates ovarian clear cell carcinoma by promoting tumor spheroid formation, cell migration and chemoresistance. Oncogene (2015) 0.84
Discovery of prognostic factors for diagnosis and treatment of epithelial-derived ovarian cancer from laying hens. J Cancer Prev (2013) 0.83
Clear cell carcinomas of the ovary: a mono-institutional study of 73 cases in China with an analysis of the prognostic significance of clinicopathological parameters and IMP3 expression. Diagn Pathol (2016) 0.82
Clear cell carcinoma of the ovary: molecular insights and future therapeutic perspectives. J Gynecol Oncol (2016) 0.82
HNF-1β in ovarian carcinomas with serous and clear cell change. Int J Gynecol Pathol (2013) 0.82
Ovarian clear cell carcinoma, outcomes by stage: The MSK experience. Gynecol Oncol (2015) 0.82
CRABP1-reduced expression is associated with poorer prognosis in serous and clear cell ovarian adenocarcinoma. J Cancer Res Clin Oncol (2010) 0.82
Tissue factor expression in ovarian cancer: implications for immunotherapy with hI-con1, a factor VII-IgGF(c) chimeric protein targeting tissue factor. Clin Exp Metastasis (2011) 0.82
Ovarian cancer: new developments in clear cell carcinoma and hopes for targeted therapy. Jpn J Clin Oncol (2015) 0.82
X-chromosome-linked inhibitor of apoptosis as a key factor for chemoresistance in clear cell carcinoma of the ovary. Br J Cancer (2014) 0.81
Successful use of next generation genomic sequencing (NGS)-directed therapy of clear cell carcinoma of the ovary (CCCO) with trametinib and metformin in a patient with chemotherapy-refractory disease. Gynecol Oncol Res Pract (2015) 0.81
Mutational status of KRAS, NRAS, and BRAF in primary clear cell ovarian carcinoma. Virchows Arch (2014) 0.81
A recurrence-predicting prognostic factor for patients with ovarian clear-cell adenocarcinoma at reproductive age. Int J Clin Oncol (2013) 0.81
Molecular changes in endometriosis-associated ovarian clear cell carcinoma. Eur J Cancer (2015) 0.80
Nutlin-3a: A Potential Therapeutic Opportunity for TP53 Wild-Type Ovarian Carcinomas. PLoS One (2015) 0.80
DNA methylation changes in epithelial ovarian cancer histotypes. Genomics (2015) 0.80
Are platinum agents, paclitaxel and irinotecan effective for clear cell carcinoma of the ovary? DNA damage detected with γH2AX induced by anticancer agents. J Ovarian Res (2012) 0.80
Immunosuppression through constitutively activated NF-κB signalling in human ovarian cancer and its reversal by an NF-κB inhibitor. Br J Cancer (2014) 0.80
Potential targets for ovarian clear cell carcinoma: a review of updates and future perspectives. Cancer Cell Int (2015) 0.79
Loss of autophagy-related protein Beclin 1 may define poor prognosis in ovarian clear cell carcinomas. Int J Oncol (2015) 0.79
Subtype specific elevated expression of hyaluronidase-1 (HYAL-1) in epithelial ovarian cancer. PLoS One (2011) 0.79
Somatic copy number alterations associated with Japanese or endometriosis in ovarian clear cell adenocarcinoma. PLoS One (2015) 0.79
Ovarian clear cell carcinoma meets metabolism; HNF-1β confers survival benefits through the Warburg effect and ROS reduction. Oncotarget (2015) 0.79
Defective hCNT1 transport contributes to gemcitabine chemoresistance in ovarian cancer subtypes: overcoming transport defects using a nanoparticle approach. Cancer Lett (2015) 0.79
The cancer stem cell marker CD133 interacts with plakoglobin and controls desmoglein-2 protein levels. PLoS One (2013) 0.79
Incidence of epithelial ovarian cancer according to histologic subtypes in Korea, 1999 to 2012. J Gynecol Oncol (2015) 0.79
Gemcitabine as a molecular targeting agent that blocks the Akt cascade in platinum-resistant ovarian cancer. J Ovarian Res (2014) 0.78
Patterns of spread of clear cell ovarian cancer: Case report and case series. Gynecol Oncol Case Rep (2013) 0.78
Demethylation of HIN-1 reverses paclitaxel-resistance of ovarian clear cell carcinoma through the AKT-mTOR signaling pathway. BMC Cancer (2015) 0.78
Aberrant expression of p27(Kip1)-interacting cell-cycle regulatory proteins in ovarian clear cell carcinomas and their precursors with special consideration of two distinct multistage clear cell carcinogenetic pathways. Virchows Arch (2009) 0.78
Genetic and molecular changes in ovarian cancer. Cancer Biol Med (2016) 0.78
Suppression of REV7 enhances cisplatin sensitivity in ovarian clear cell carcinoma cells. Cancer Sci (2014) 0.77
Metabolic alterations caused by HNF1β expression in ovarian clear cell carcinoma contribute to cell survival. Oncotarget (2015) 0.77
A Case of Stage III c Ovarian Clear Cell Carcinoma: The Role for Predictive Biomarkers and Targeted Therapies. Int J Mol Sci (2013) 0.77
Transcriptional upregulation of HNF-1β by NF-κB in ovarian clear cell carcinoma modulates susceptibility to apoptosis through alteration in bcl-2 expression. Lab Invest (2015) 0.77
Targeting FXYD2 by cardiac glycosides potently blocks tumor growth in ovarian clear cell carcinoma. Oncotarget (2016) 0.77
An allelotype analysis indicating the presence of two distinct ovarian clear-cell carcinogenic pathways: endometriosis-associated pathway vs. clear-cell adenofibroma-associated pathway. Virchows Arch (2009) 0.77
Topophore C: a liposomal nanoparticle formulation of topotecan for treatment of ovarian cancer. Invest New Drugs (2012) 0.77
Prognostic value of histological type in stage IV ovarian carcinoma: a retrospective analysis of 223 patients. Br J Cancer (2015) 0.76
Overexpression of WDR62 is associated with centrosome amplification in human ovarian cancer. J Ovarian Res (2013) 0.76
Comprehensive assessment of the expression of the SWI/SNF complex defines two distinct prognostic subtypes of ovarian clear cell carcinoma. Oncotarget (2016) 0.76
Analysis of the antitumor activity of gemcitabine and carboplatin against ovarian clear-cell carcinoma using the DNA damage marker γH2AX. Onco Targets Ther (2013) 0.75
IDH1 R132C mutation is detected in clear cell hepatocellular carcinoma by pyrosequencing. World J Surg Oncol (2017) 0.75
Preclinical Investigations of PM01183 (Lurbinectedin) as a Single Agent or in Combination with Other Anticancer Agents for Clear Cell Carcinoma of the Ovary. PLoS One (2016) 0.75
Systematic assessment of HER2/neu in gynecologic neoplasms, an institutional experience. Diagn Pathol (2016) 0.75
Differentiation of epithelial ovarian cancer subtypes by use of imaging and clinical data: a detailed analysis. Cancer Imaging (2016) 0.75
Inhibition of autophagy protein LC3A as a therapeutic target in ovarian clear cell carcinomas. J Gynecol Oncol (2017) 0.75
ARID1A gene silencing reduces the sensitivity of ovarian clear cell carcinoma to cisplatin. Exp Ther Med (2016) 0.75
Dietary fat intake and ovarian cancer risk: a meta-analysis of epidemiological studies. Oncotarget (2016) 0.75
Molecular Characterization of Epithelial Ovarian Cancer: Implications for Diagnosis and Treatment. Int J Mol Sci (2016) 0.75
The transcriptional landscape of the mammalian genome. Science (2005) 37.63
Antisense transcription in the mammalian transcriptome. Science (2005) 15.69
Nitric oxide: an endogenous modulator of leukocyte adhesion. Proc Natl Acad Sci U S A (1991) 8.04
Peroral endoscopic myotomy (POEM) for esophageal achalasia. Endoscopy (2010) 7.10
Glutamine repeats as polar zippers: their possible role in inherited neurodegenerative diseases. Proc Natl Acad Sci U S A (1994) 6.96
Nucleotide sequence of cloned cDNA for bovine corticotropin-beta-lipotropin precursor. Nature (1979) 6.56
Peptidyl-prolyl cis-trans isomerase is the cyclosporin A-binding protein cyclophilin. Nature (1989) 5.86
Prediction of acute left main coronary artery obstruction by 12-lead electrocardiography. ST segment elevation in lead aVR with less ST segment elevation in lead V(1). J Am Coll Cardiol (2001) 4.81
Reconstitution of G1 cyclin ubiquitination with complexes containing SCFGrr1 and Rbx1. Science (1999) 4.65
A standard reference frame for the description of nucleic acid base-pair geometry. J Mol Biol (2001) 4.29
Clinically mild encephalitis/encephalopathy with a reversible splenial lesion. Neurology (2004) 4.24
The PILATUS 1M detector. J Synchrotron Radiat (2006) 4.16
Complete nucleotide sequence of the Japanese encephalitis virus genome RNA. Virology (1987) 3.96
Nicking-closing activity associated with bacteriophage lambda int gene product. Proc Natl Acad Sci U S A (1979) 3.88
Light-induced resetting of a mammalian circadian clock is associated with rapid induction of the mPer1 transcript. Cell (1997) 3.79
An endothelial receptor for oxidized low-density lipoprotein. Nature (1997) 3.76
Degradation of p53 by adenovirus E4orf6 and E1B55K proteins occurs via a novel mechanism involving a Cullin-containing complex. Genes Dev (2001) 3.67
Cross-contamination potential with dental equipment. Lancet (1992) 3.55
Identification of the von Hippel-lindau tumor-suppressor protein as part of an active E3 ubiquitin ligase complex. Proc Natl Acad Sci U S A (1999) 3.43
A new form of amyloid protein associated with chronic hemodialysis was identified as beta 2-microglobulin. Biochem Biophys Res Commun (1985) 3.40
Probucol prevents the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbit, an animal model for familial hypercholesterolemia. Proc Natl Acad Sci U S A (1987) 3.32
Regulation of hypoxia-inducible mRNAs by the von Hippel-Lindau tumor suppressor protein requires binding to complexes containing elongins B/C and Cul2. Mol Cell Biol (1998) 3.30
Bacterial genomic reorganization upon DNA replication. Science (2001) 3.25
Alymphoplasia is caused by a point mutation in the mouse gene encoding Nf-kappa b-inducing kinase. Nat Genet (1999) 3.17
Apoptosis induction by antisense oligonucleotides against miR-17-5p and miR-20a in lung cancers overexpressing miR-17-92. Oncogene (2007) 3.11
A novel transgenic technique that allows specific marking of the neural crest cell lineage in mice. Dev Biol (1999) 3.11
Development of an MRI-compatible needle insertion manipulator for stereotactic neurosurgery. J Image Guid Surg (1995) 3.07
Visualization of neurogenesis in the central nervous system using nestin promoter-GFP transgenic mice. Neuroreport (2000) 3.04
Increased insulin sensitivity and hypoglycaemia in mice lacking the p85 alpha subunit of phosphoinositide 3-kinase. Nat Genet (1999) 2.81
The bacteriophage lambda int gene product. A filter assay for genetic recombination, purification of int, and specific binding to DNA. J Biol Chem (1978) 2.81
Quantum Hall effect in polar oxide heterostructures. Science (2007) 2.73
Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis. Nature (2002) 2.71
Defective lipoprotein receptors and atherosclerosis. Lessons from an animal counterpart of familial hypercholesterolemia. N Engl J Med (1983) 2.67
Regulation of expression of the galactose gene cluster in Saccharomyces cerevisiae. Isolation and characterization of the regulatory gene GAL4. Mol Gen Genet (1983) 2.66
Two regulatory proteins that bind to the basic transcription element (BTE), a GC box sequence in the promoter region of the rat P-4501A1 gene. EMBO J (1992) 2.65
Interaction of int protein with specific sites on lambda att DNA. Cell (1979) 2.61
Delayed clearance of very low density and intermediate density lipoproteins with enhanced conversion to low density lipoprotein in WHHL rabbits. Proc Natl Acad Sci U S A (1982) 2.60
Host resistance in sepsis and trauma. Ann Surg (1975) 2.56
A novel mode of DNA recognition by a beta-sheet revealed by the solution structure of the GCC-box binding domain in complex with DNA. EMBO J (1998) 2.48
Hepatic uptake of chylomicron remnants in WHHL rabbits: a mechanism genetically distinct from the low density lipoprotein receptor. Proc Natl Acad Sci U S A (1982) 2.43
Antibodies to adult T-cell leukemia-virus-associated antigen (ATLA) in sera from patients with ATL and controls in Japan: a nation-wide sero-epidemiologic study. Int J Cancer (1982) 2.39
Expression of SR-PSOX, a novel cell-surface scavenger receptor for phosphatidylserine and oxidized LDL in human atherosclerotic lesions. Arterioscler Thromb Vasc Biol (2001) 2.39
Spectrodensitometric determination of trichothecene mycotoxins with 4-(p-nitrobenzyl)pyridine on silica gel thin-layer chromatograms. J Chromatogr (1979) 2.38
Modulation of the Ca2 permeable cation channel TRPV4 by cytochrome P450 epoxygenases in vascular endothelium. Circ Res (2005) 2.38
Mutually exclusive expression of odorant receptor transgenes. Nat Neurosci (2000) 2.36
In-vitro antibacterial susceptibility of bacteria taken from infected root dentine to a mixture of ciprofloxacin, metronidazole and minocycline. Int Endod J (1996) 2.33
Truncated CBP protein leads to classical Rubinstein-Taybi syndrome phenotypes in mice: implications for a dominant-negative mechanism. Hum Mol Genet (1999) 2.32
The nucleotide sequence of the promoter and the amino-terminal region of alkaline phosphatase structural gene (phoA) of Escherichia coli. Nucleic Acids Res (1981) 2.32
Physiological role of silent receptors of atrial natriuretic factor. Science (1987) 2.31
Feedback regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase in livers of mice treated with mevinolin, a competitive inhibitor of the reductase. J Clin Invest (1980) 2.26
Long-term proliferating early pre B cell lines and clones with the potential to develop to surface Ig-positive, mitogen reactive B cells in vitro and in vivo. EMBO J (1991) 2.25
Altered cochlear fibrocytes in a mouse model of DFN3 nonsyndromic deafness. Science (1999) 2.25
Induction of microRNAs, mir-155, mir-222, mir-424 and mir-503, promotes monocytic differentiation through combinatorial regulation. Leukemia (2009) 2.24
'SPKK' motifs prefer to bind to DNA at A/T-rich sites. EMBO J (1989) 2.24
Degradation of p27(Kip1) at the G(0)-G(1) transition mediated by a Skp2-independent ubiquitination pathway. J Biol Chem (2001) 2.23
Biophysical characteristics of HIMAC clinical irradiation system for heavy-ion radiation therapy. Int J Radiat Oncol Biol Phys (1999) 2.19
Protease nexin-II, a potent antichymotrypsin, shows identity to amyloid beta-protein precursor. Nature (1989) 2.17
Impaired chemosensitivity and perception of dyspnoea in Parkinson's disease. Lancet (2000) 2.17
Activation of the Keap1/Nrf2 pathway for neuroprotection by electrophilic [correction of electrophillic] phase II inducers. Proc Natl Acad Sci U S A (2006) 2.15
Catheter ablation in patients with multiple and unstable ventricular tachycardias after myocardial infarction: short ablation lines guided by reentry circuit isthmuses and sinus rhythm mapping. Circulation (2001) 2.12
Proline-directed and non-proline-directed phosphorylation of PHF-tau. J Biol Chem (1995) 2.09
Deficiency of low density lipoprotein receptors in liver and adrenal gland of the WHHL rabbit, an animal model of familial hypercholesterolemia. Proc Natl Acad Sci U S A (1981) 2.08
Junctional adhesion molecule (JAM) binds to PAR-3: a possible mechanism for the recruitment of PAR-3 to tight junctions. J Cell Biol (2001) 2.06
Yeast plasmid requires a cis-acting locus and two plasmid proteins for its stable maintenance. Cell (1983) 2.04
Genetic control of bacteriophage T4 baseplate morphogenesis. I. Sequential assembly of the major precursor, in vivo and in vitro. J Mol Biol (1975) 2.03
LST-2, a human liver-specific organic anion transporter, determines methotrexate sensitivity in gastrointestinal cancers. Gastroenterology (2001) 2.02
Prenatal DNA diagnosis of a single-gene disorder from maternal plasma. Lancet (2000) 2.01
Analysis of platelet abnormalities in uremia with and without Glanzmann's thrombasthenia. Nephron (1994) 2.00
Solitary fibrous tumour: significance of p53 and CD34 immunoreactivity in its malignant transformation. Histopathology (1998) 2.00
Experimental and natural infection with Bartonella henselae in domestic cats. Comp Immunol Microbiol Infect Dis (1997) 1.99
Evidence that errors made by DNA polymerase alpha are corrected by DNA polymerase delta. Curr Biol (2006) 1.98
Impaired receptor-mediated catabolism of low density lipoprotein in the WHHL rabbit, an animal model of familial hypercholesterolemia. Proc Natl Acad Sci U S A (1982) 1.98
A human homologue of the yeast GST1 gene codes for a GTP-binding protein and is expressed in a proliferation-dependent manner in mammalian cells. EMBO J (1989) 1.97
DNA binding of PhoB and its interaction with RNA polymerase. J Mol Biol (1996) 1.97
Relation between use of health check ups starting in middle age and demand for inpatient care by elderly people in Japan. BMJ (1991) 1.96
Possible function of Ah receptor nuclear translocator (Arnt) homodimer in transcriptional regulation. Proc Natl Acad Sci U S A (1995) 1.94
A novel protein phosphatase-1 inhibitory protein potentiated by protein kinase C. Isolation from porcine aorta media and characterization. J Biochem (1995) 1.92
A light-independent oscillatory gene mPer3 in mouse SCN and OVLT. EMBO J (1998) 1.92
Concentration and composition of lipoproteins in blood plasma of the WHHL rabbit. An animal model of human familial hypercholesterolemia. Arteriosclerosis (1983) 1.90
Yeast Ull1/Siz1 is a novel SUMO1/Smt3 ligase for septin components and functions as an adaptor between conjugating enzyme and substrates. J Biol Chem (2001) 1.89
Protein sequence and mass spectrometric analyses of tau in the Alzheimer's disease brain. J Biol Chem (1992) 1.89
Prokaryotic DNA polymerase I: evolution, structure, and "base flipping" mechanism for nucleotide selection. J Mol Biol (2001) 1.88
Expression of lectinlike oxidized low-density lipoprotein receptor-1 in human atherosclerotic lesions. Circulation (1999) 1.88
Identification of a novel gene family encoding human liver-specific organic anion transporter LST-1. J Biol Chem (1999) 1.87
NK105, a paclitaxel-incorporating micellar nanoparticle formulation, can extend in vivo antitumour activity and reduce the neurotoxicity of paclitaxel. Br J Cancer (2005) 1.87
ONO-5046, a novel inhibitor of human neutrophil elastase. Biochem Biophys Res Commun (1991) 1.85
Integrative recombination of bacteriophage lambda: requirement for supertwisted DNA in vivo and characterization of int. Cold Spring Harb Symp Quant Biol (1979) 1.84
Lectin-like oxidized low-density lipoprotein receptor 1 mediates phagocytosis of aged/apoptotic cells in endothelial cells. Proc Natl Acad Sci U S A (1998) 1.84
Functional repression of Islet-2 by disruption of complex with Ldb impairs peripheral axonal outgrowth in embryonic zebrafish. Neuron (2001) 1.83
Promotion of parallel DNA quadruplexes by a yeast telomere binding protein: a circular dichroism study. Proc Natl Acad Sci U S A (1994) 1.83
Scavenging effects of tea catechins and their derivatives on 1,1-diphenyl-2-picrylhydrazyl radical. Free Radic Biol Med (1996) 1.82
Transposable element in fish. Nature (1996) 1.80
Aneurysms at nonbranching sites in the surpaclinoid portion of the internal carotid artery: internal carotid artery trunk aneurysms. Neurosurgery (2000) 1.80
Expressions of PDGF receptor alpha, c-Kit and Flk1 genes clustering in mouse chromosome 5 define distinct subsets of nascent mesodermal cells. Dev Growth Differ (1997) 1.79
Unusual priming mechanism of RNA-directed DNA synthesis in copia retrovirus-like particles of Drosophila. Nature (1986) 1.79
Production of a monoclonal antibody useful in the molecular characterization of murine T-cell-replacing factor/B-cell growth factor II. Proc Natl Acad Sci U S A (1987) 1.79
Dioxin binding activities of polymorphic forms of mouse and human arylhydrocarbon receptors. J Biol Chem (1994) 1.78
Molecular cloning of a novel scavenger receptor for oxidized low density lipoprotein, SR-PSOX, on macrophages. J Biol Chem (2000) 1.76
T cell-replacing factor (TRF)/interleukin 5 (IL-5): molecular and functional properties. Immunol Rev (1988) 1.76